NanoViricides Inc. (NNVC)

[changes_iv]

In a pandemic emergency in the US, the government has a program called "emergency use authorization", which means that if a drug has completed Phase I/IIa safety and efficacy trials, and it is manufactured under current good manufacturing practice (cGMP) conditions, then the government is eligible to buy the product to treat people with the current circulating strain of the flu virus.

"That is why we are pushing now to get FluCide into human trials as quickly as possible," added Dr. Eugene Seymour, CEO NanoViricides, Inc.

NanoViricides said it still has to perform toxicology studies for FluCide, required for the FDA to move forward.

Once FluCide is on its targeted FDA path, NanoViricides expects its other nanoviricide drugs in the pipeline to follow, with one expected "every six months or so".

If Nanoviricides, Inc. is already moving forward with DengueCide, how long will it be before they announce that BASi GLP Toxicology and Safety Studies have begun? For the disruptive and transformational technology of nanoviricides,...soon, IMHO!

"...we are a company...with the ability to rapidly create drugs, and when I say rapidly create drugs I'm talking about weeks instead of years..." ~ Dr. Eugene Seymour, CEO Nanoviricides, Inc.

"by the way, I'm sure that when you think human trials for drugs you think of hundreds of millions of dollars and years of time, well in this case because the disease only lasts a week, two weeks,...that it is possible to complete human trials in the space of a few short months...four parts to the human trials" ~ Dr. Eugene Seymour, CEO Nanoviricides, Inc.